J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION

Size: px
Start display at page:

Download "J Clin Oncol 24:4158-4162. 2006 by American Society of Clinical Oncology INTRODUCTION"

Transcription

1 VOLUME 24 NUMBER 25 SEPTEMBER JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Impact of a Multi-Disciplinary Patient Education Session on Accrual to a Difficult Clinical Trial: The Toronto Experience With the Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial Kris Wallace, Neil Fleshner, Michael Jewett, Joan Basiuk, and Juanita Crook From the Departments of Radiation Medicine and the Division of Urology and Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada. Submitted March 1, 2006; accepted July 6, Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Address reprint requests to Juanita Crook, MD, FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, Canada, M5G 2M9; juanita.crook@rmp.uhn.on.ca by American Society of Clinical Oncology X/06/ /$20.00 DOI: /JCO A B S T R A C T Purpose Random assignment to clinical trials involving different treatment modalities can be difficult. We describe our experience with the Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial (SPIRIT; ACOSOG Z0070 NCIC PR10), a randomized trial for early-stage prostate cancer comparing radical prostatectomy (RP), and brachytherapy (BT). A multidisciplinary educational session was developed to improve patient understanding of treatment options and to facilitate accrual. Patients and Methods Prostate cancer referrals were screened and men who met favorable risk criteria (T1c/T2a, prostate-specific antigen [PSA] 10 ng/ml, Gleason 6) were invited to a structured education session before a specialty consultation. Men and their partners viewed the SPIRIT informedconsent video and heard from a cancer patient who described his participation in a randomized trial. Then, a urologist and radiation oncologist together compared and contrasted RP and BT to establish the rationale for the trial. Results In May 2002, SPIRIT opened for accrual and was endorsed by the University Health Network urologists and radiation oncologists. The first 27 eligible patients were approached about SPIRIT, consulted both specialties, and viewed an educational video. No patients consented. The multidisciplinary education session was then introduced. Forty-seven education sessions with 263 patients resulted in 34 consents. Of 203 patients who were suitable for the study but declined random assignment, 62 chose surgery, 94 chose brachytherapy, three patients chose external radiotherapy, and 11 chose no treatment. Consent rates for eligible and suitable patients were one in six. Conclusion Men who understand their treatment options and trial rationale as presented jointly by representative specialists from competing treatment modalities may be better equipped to make an informed decision and are more likely to consent to random assignment. J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION Of the 250,000 men diagnosed with prostate cancer per annum in North America, approximately 60% have early-stage favorable disease. Many make treatment decisions based on anecdotal information or unsubstantiated opinion. No randomized clinical trials have previously addressed relative efficacy or quality of life following radical prostatectomy and brachytherapy. 1-5 Therefore, SPIRIT (Surgical Prostatectomy versus Interstitial Radiation Intervention Trial; American College of Surgeons Oncology Group [ACOSOG] Z0070 National Cancer Institute of Canada [NCIC] PR10) was designed to randomly assign men with early-stage prostate cancer to one of these two options. The trial received Cancer Therapy Evaluation Program (CTEP; National Cancer Institute, Bethesda, MD) approval in 2002 and subsequently opened in 31 centers across North America. ACOSOG developed and distributed a patient education video and brochure. As initial experience with accrual was disappointing, we developed a small-group patient education session to provide the balanced information required for informed decision. Sessions were held weekly for new patients with a goal to compare radical prostatectomy and 4158

2 Toronto Experience With SPIRIT brachytherapy in a multidisciplinary setting, to establish the rationale for randomized trials in general, and to introduce SPIRIT. PATIENTS AND METHODS SPIRIT was launched in May 2002 at the Princess Margaret Hospital (Toronto, Canada). To identify eligible patients, urology and brachytherapy prostate cancer referrals were screened by the clinical research associate (CRA). Eligible patients had Gleason score 6, prostate-specific antigen (PSA) 10.0 ng/ml, prostate transrectal ultrasound (TRUS) volume 60 cc, and biopsy less than 120 days previously. The CRA met individually with each patient to introduce the concept of SPIRIT and view the informed consent video. In addition, each patient was approached by their urologist and/or radiation oncologist about the study. Over 3 months, 27 patients viewed the video but none consented to random assignment. Review of this experience in a multidisciplinary setting resulted in the institution of education sessions. The 90-minute education session was facilitated by the CRA for a maximum of 10 patients. Patients were advised to bring a companion and to attend before their individual consultations with specialists. 6 Chairs were arranged in the session in a semi-circle to encourage interactive dialogue. At the initial sessions, after screening the 25-minute SPIRIT Informed Consent Video (ACOSOG), a prostate cancer survivor and clinical trial participant shared his view of clinical trials. In later sessions, a SPIRIT participant discussed his decision-making process with the group. The intention was not to focus on anecdotal details, but to communicate the reasons for his decision and any benefits he felt he had gained. Next, the urologist and radiation oncologist joined the session. Using a PowerPoint (Microsoft Corporation, Redmond, WA) presentation as a guide, the urologist and radiation oncologist jointly compared and contrasted their modalities and introduced the concept of a randomized trial. The emphasis was on understanding surgery and brachytherapy, with randomization presented as a third option. The session addressed procedure details and recovery, urinary and erectile function, PSA response, and salvage therapy. Only if deemed equally suitable for surgery and brachytherapy, would SPIRIT be an option for the patient. The final portion of the session was interactive. Questions were encouraged, although those of a personal nature were deferred until the individual consultation sessions. Comfort with both treatment options and a willingness to undergo either treatment was necessary for consent. While attendees completed a questionnaire to evaluate the session, the CRA ensured that each attendee had a clear schedule of upcoming appointments and distributed the SPIRIT brochure (ACOSOG) and PowerPoint outline. All handouts and questionnaires received institutional ethics approval. Following closure of SPIRIT, 190 session attendees were contacted by the CRA to assess treatment satisfaction and to record demographics. RESULTS Before closure of SPIRIT by ACOSOG in April 2004, 263 patients attended 47 sessions, resulting in 34 consents and 32 random assignments. One patient who consented was deemed ineligible before random assignment, and the final consent occurred on the day of study suspension. Forty-five session attendees were assessed as unsuitable for SPIRIT, usually because of voiding dysfunction which rendered brachytherapy inadvisable, or medical comorbidities that could complicate surgery. Fifteen patients were still undecided at study closure. Of the 203 patients who were suitable but declined SPIRIT, 62 chose surgery, 94 chose brachytherapy, three chose external radiotherapy, and 11 opted for watchful waiting. The consent rate for eligible and suitable patients from the launch of the educational intervention was one in six. The questionnaire to assess the education intervention from the patient s perspective was introduced in May 2003 (Appendix). From 27 sessions, 182 questionnaires were completed. Patients ranked statements on a scale of increasing agreement from 1 to 5. The global response was very positive, with 79% agreeing or strongly agreeing that their understanding of prostate cancer (median, 5; mean, 4.15) and their treatment options (median, 5; mean, 4.09) had improved. Similarly, the information provided was deemed helpful in making a decision about treatment (median, 5; mean, 3.96). Following closure of the trial, the CRA contacted 190 attendees to assess their treatment satisfaction and demographics (SPIRIT, 34; radical prostatectomy [RP] choice, 62; brachytherapy [BT] choice, 94). There were no significant differences among the three groups concerning urban/rural residence (P.119), education level (P.155), marital status (P.75), or treatment satisfaction (P.61; Table 1). Specifically, 82% of those patients who accepted random assignments were city dwellers, 85% were married, 79% had postsecondary education, and 94% would recommend their treatment to a friend. Treatment satisfaction was very high in all three groups. DISCUSSION Many factors influence clinical trial accrual. In the palliative setting, exhaustion of standard modalities may position a clinical trial as a last hope. Clearly this does not apply to early-stage curable disease, for which many options exist. To consider a randomized trial, patients must understand their options, the pros and cons of each option, and the reason for the trial. Accrual will result if the patient and their family perceive that the treatments being compared are not dissimilar, and/or if patients are equally comfortable with either option. Many patients would like to benefit others in the future, 7 if they can do so without risk to themselves. Trust in the medical team and a thorough understanding of the issues are essential Demographic characteristics that have been reported to be associated with a willingness to participate in clinical trials are older age, male sex, lower educationl level, and lower socioeconomic background. 6,12,13 Llewellyn-Thomas et al 14 reported that patients with greater knowledge about a trial were less willing to participate. In contrast, Ellis 15 found that poor understanding of the concept of clinical trials, and not the details of the trial itself, was a barrier. A cross-sectional survey of a breast cancer screening clinic showed that younger women with a better understanding of the issues, who wanted an active role in decision making, were more likely to participate. Trial endorsement by a high-profile national organization also increased participation. Our experience with SPIRIT would support the view that greater knowledge and understanding have a positive effect on accrual. None of the team members associated with the SPIRIT education sessions have a background in patient education, nor was advice sought from an educator. Our goal was to ensure consistency in the information presented by the disciplines involved. Catt et al 16 have shown that consistency of approach may be assumed among members of a health care team but might not be perceived by the patient. Patients often ask the same questions to multiple health care professionals, either because they forget, or did not understand, or are seeking reassurance. Recollection of only parts of an explanation may give a false impression. We felt it was essential that the specialty consultants be available

3 Wallace et al Table 1. Demographics and Follow-Up Satisfaction With Treatment Decision, Based on Men Having Brachytherapy (n 94), Radical Prostatectomy (n 62), and Consenting to SPIRIT (n 34) Question BT % RP % SPIRIT % P Who attended the SPIRIT education session with the patient? Someone No one No response Urban/GTA or rural address? Urban Rural Are you living in a conjugal relationship? Yes No Highest level of education Elementary Secondary Postsecondary Overall, I am satisfied with the treatment I received Very Somewhat Not at all No response % Would you recommend this treatment to a friend? Yes No Abbreviations: SPIRIT, Surgical Prostatectomy versus Interstitial Radiation Intervention Trial; BT, brachytherapy; RP, radical prostatectomy; GTA, greater Toronto area. at the sessions. Although the primary goal was patient education, the motivation was the trial. We believed that a fully informed patient would be able to appreciate the pros and cons of each modality and thus be more likely to accept random assignment. This commitment to education is time-consuming and impractical on a one-to-one basis but is feasible in a small group setting. The demographics of men consenting to SPIRIT indicate that 85% were urban residents and 79% had postsecondary education, suggesting a potential to benefit from such education measures. One of the major barriers to trial accrual is physicians attitudes toward clinical trials. 17,18 Offering a clinical trial may appear to conflict with individual decision-making and clinical judgment and requires acknowledgment of an uncertainty about the therapeutic benefit or superiority of one treatment over another, 19,20 especially in a trial like SPIRIT where competing modalities are compared. The mutual respect that was fundamental to the multidisciplinary format of our patient education sessions perhaps helped to overcome the professional reluctance to admit uncertainty. Difficult trials that have been successfully completed in the past have changed clinical practice. The National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-06 randomly assigned 2,105 women with breast cancer to total mastectomy or lumpectomy treatment modalities, with or without irradiation. After 12 years of followup, lumpectomy followed by breast irradiation was proven to be appropriate therapy for women in this cohort, thereby sparing countless women a total mastectomy. 21 Another difficult trial was the prospective, multicenter North American Asymptomatic Carotid Artery Stenosis (ACAS) Study in which 1,659 patients with carotid artery stenosis were randomly assigned to either endarterectomy or medical therapy. The relative risk reduction of 53% in the surgical arm changed the standard of care. 22 These trials illustrate major challenges in accrual with comparison of options that from a patient s perspective are very dissimilar. Successful completion has profoundly affected the standard of practice. The urologists and radiation oncologists involved in SPIRIT put aside their biases and professional rivalries to address fundamental questions concerning radical prostatectomy and brachytherapy. Despite their commitment, it became clear after only a few weeks of presenting this trial in a standard fashion to eligible patients that a different approach was necessary. This education intervention was the result. It began as a free-form education session to inform a small group of men and their family members about early-stage prostate cancer, to compare and contrast surgery and brachytherapy, and to explain the reason for the randomized trial. Over the ensuing weeks, a PowerPoint framework was developed, incorporating responses to frequently asked questions, and to the reasons frequently cited for selecting one modality over the other. We tried to ensure that the session was worthwhile for all attendees, regardless of their final treatment decision. When patients were invited to the education session, they were encouraged to bring a relative or friend. This tactic encourages further discussion and is key to assimilating and understanding information. 11,23 Patient feedback was very positive; a tribute to the specialists efforts to maintain a neutral tone. Attendees should feel that they are being informed of their treatment options, that randomization is one option, but that there is no pressure to enter the trial JOURNAL OF CLINICAL ONCOLOGY

4 Toronto Experience With SPIRIT The medical literature reveals clinical equipoise between radical prostatectomy and brachytherapy, but establishing that balance for the individual patient is vital to the success of trials such as SPIRIT. This balance was evident in the joint multidisciplinary presentation; the presence of the urologist and radiation oncologist together spoke volumes to the attendees. Even men who came to the session with their minds made up about their treatment decisions, often went home to reconsider. The interactive nature of the session worked in favor of the trialasmenwoulddiscussamongthemselvesthereasonsfortheirchoices. We acknowledge the differences in health care systems between countries, and in individual settings. The education intervention should be tailored to the needs of the community and the institution. Practice in a multidisciplinary environment may lend itself more readily to the establishment of a multidisciplinary session. Time spent in the small group setting expedites the subsequent consultation, allowing the specialist to focus on matters specific to that particular patient. SPIRIT did not meet accrual expectations and was closed by the American College of Surgeons Oncology Group in April 2004, having randomly assigned only 56 patients in a 2-year period, 15 patients from American centers and 41 from Canada. The disparity between the successful accrual with the education session and that seen elsewhere led to many discussions on the implementation of this approach elsewhere. The PowerPoint presentation was shared with interested centers. Internet access to a video-taped session was also considered. One American and one other Canadian center instituted a similar session and achieved improved accrual with six consents each. Admittedly, a randomized trial comparing radical prostatectomy and brachytherapy is an ambitious undertaking. The lesson learned is that difficult clinical trials may need a different approach. Evidencebased medicine demands evidence-based answers, and so do patients. The Toronto experience with SPIRIT suggests that men who are fully informed and understand their treatment options as presented jointly in an unbiased manner by representative specialists from competing modalities are better equipped to make an informed decision. And in our experience, for one man in six, that informed decision was consent to random assignment. REFERENCES 1. Davis JW, Kuban DA, Lynch DF, et al: Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 166: , Stone NN, Stock RG: Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Urol Clin North Am 30: , Bacon CG, Giovannucci E, Testa M, et al: The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 166: , Lee WR, Hall MC, McQuellan RP, et al: A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 51: , Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20: , Verheggen FW, Nieman F, Jonkers R: Determinants of patient participation in clinical studies requiring informed consent: Why patients enter a clinical trial. Patient Educ Couns 35: , Jenkins V, Fallowfield L: Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 82: , Chard JA, Lilford RJ: The use of equipoise in clinical trials. Soc Sci Med 47: , Mills N, et al: Perceptions of equipoise are crucial to trial participation: A qualitative study of men in the ProtecT study. Control Clin Trials 24: , Movsas B, Moughan J, Owen J, et al: Who enrolls onto clinical oncology trials? A patterns of care study analysis. Int J Radiat Oncol Biol Phys 57:S214, 2003 (suppl 2) 11. Sanchez S, Salazar G, Tijero M, et al.: Informed consent procedures: Responsibilities of researchers in developing countries. Bioethics 15: , Henzlova MJ, Blackburn GH, Bradley EJ, et al: Patient perception of a long-term clinical trial: Experience using a close-out questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial SOLVD Close-Out Working Group. Control Clin Trials 15: , Bevan EG, Chee LC, McGhee SM, et al: Patients attitudes to participation in clinical trials. Br J Clin Pharmacol 35: , Llewellyn-Thomas HA, Thiel EC, Sem FW, et al: Presenting clinical trial information: A comparison of methods. Patient Educ Couns 25:97-107, Ellis PM: Attitudes towards and participation in randomised clinical trials in oncology: A review of the literature. Ann Oncol 11: , Catt S, Fallowfield L, Jenkins V, et al: The informational roles and psychological health of members of 10 oncology multidisciplinary teams in the UK. Br J Cancer 93: , Hunter CP, Frelick RW, Feldman AR, et al: Selection factors in clinical trials: Results from the Community Clinical Oncology Program Physician s Patient Log. Cancer Treat Rep 71: , Ellis PM, Butow PN, Tattersall MH, et al: Randomized clinical trials in oncology: Understanding and attitudes predict willingness to participate. J Clin Oncol 19: , Fallowfield L: Can we improve the professional and personal fulfillment of doctors in cancer medicine? Br J Cancer 71: , Benson AB 3rd, Pregler JP, Bean JA, et al: Oncologists reluctance to accrue patients onto clinical trials: An Illinois Cancer Center study. J Clin Oncol 9: , Fisher B: Clinical trials for the evaluation of cancer therapy. Cancer 54: , 1984 (suppl 11) 22. Mast H, Chambless LE, Mohr JP, et al: Indications for endarterectomy in asymptomatic stenoses of the internal or common carotid artery: Results of the North American ACAS Study [in German]. Zentralbl Chir 121: , Gorelick PB, Harris Y, Burnett B, et al: The recruitment triangle: Reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial: An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc 90: , 1998 Appendix The Appendix is included in the full-text version of this article, available online at It is not included in the PDF version (via Adobe Reader ). Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest

5 Wallace et al Author Contributions Conception and design: Neil Fleshner, Juanita Crook Administrative support: Joan Basiuk Provision of study materials or patients: Kris Wallace, Neil Fleshner, Michael Jewett, Joan Basiuk, Juanita Crook Collection and assembly of data: Kris Wallace Data analysis and interpretation: Neil Fleshner, Juanita Crook Manuscript writing: Kris Wallace, Juanita Crook Final approval of manuscript: Kris Wallace, Neil Fleshner, Michael Jewett, Joan Basiuk, Juanita Crook 4162 JOURNAL OF CLINICAL ONCOLOGY

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Guidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer

Guidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer Guidelines for Cancer Prevention, Early detection & Screening Prostate Cancer Intervention Comments & Recommendations For primary prevention, it has been suggested that diets low in meat & other fatty

More information

Prostate Cancer Screening in Taiwan: a must

Prostate Cancer Screening in Taiwan: a must Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally

More information

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:

More information

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

Does my patient need more therapy after prostate cancer surgery?

Does my patient need more therapy after prostate cancer surgery? Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier

More information

Official reprint from UpToDate www.uptodate.com 2013 UpToDate

Official reprint from UpToDate www.uptodate.com 2013 UpToDate Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek

More information

The 4Kscore blood test for risk of aggressive prostate cancer

The 4Kscore blood test for risk of aggressive prostate cancer The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6

More information

Questions to ask your doctor. about Prostate Cancer and selecting a treatment facility

Questions to ask your doctor. about Prostate Cancer and selecting a treatment facility Questions to ask your doctor about Prostate Cancer and selecting a treatment facility The Basics Establishing an open dialogue with a doctor provides you with the opportunity to learn specific information

More information

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients? Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance

More information

Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding

Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

An Introduction to PROSTATE CANCER

An Introduction to PROSTATE CANCER An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the

More information

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light

More information

There must be an appropriate administrative structure for each residency program.

There must be an appropriate administrative structure for each residency program. Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation

More information

Early Prostate Cancer: Questions and Answers. Key Points

Early Prostate Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:

More information

Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15.

Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15. Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15. CLINICAL CASE The Debate Over Prostate Cancer Screening Guidelines Commentary by Karen E. Hoffman,

More information

J Clin Oncol 24:1860-1867. 2006 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24:1860-1867. 2006 by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 12 APRIL 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Factors Associated With Participation in Breast Cancer Treatment Clinical Trials Nancy E. Avis, Kevin W. Smith,

More information

Prostate Cancer Screening. A Decision Guide

Prostate Cancer Screening. A Decision Guide Prostate Cancer Screening A Decision Guide This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Is screening right for you?

More information

PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa

PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme

More information

Breast Health Program

Breast Health Program Breast Health Program Working together, for your health. Breast Health Program The Breast Health Program at The University of Arizona Cancer Center offers patients a personalized approach to breast cancer,

More information

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online

More information

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for

More information

Prostate Cancer Screening. A Decision Guide for African Americans

Prostate Cancer Screening. A Decision Guide for African Americans Prostate Cancer Screening A Decision Guide for African Americans This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Published

More information

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood

More information

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth

More information

NCCN Prostate Cancer Early Detection Guideline

NCCN Prostate Cancer Early Detection Guideline NCCN Prostate Cancer Early Detection Guideline Joan McClure Senior Vice President National Comprehensive Cancer Network African American Prostate Cancer Disparity Summit September 22, 2006 Washington,

More information

Outcome analysis of breast cancer patients who declined evidence-based treatment

Outcome analysis of breast cancer patients who declined evidence-based treatment Joseph et al. World Journal of Surgical Oncology 2012, 10:118 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Outcome analysis of breast cancer patients who declined evidence-based treatment Kurian

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Cancer Expert Working Group on Cancer Prevention and Screening Screening for Prostate Cancer Information for men and their families 1 What is the prostate? 2 What is prostate cancer? prostate The prostate

More information

Prostate Cancer Treatment: What s Best for You?

Prostate Cancer Treatment: What s Best for You? Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.

More information

Prostate Cancer Treatment Comparison

Prostate Cancer Treatment Comparison Prostate Cancer Treatment Comparison Treatment Comparative Data Outcome Comparison: Surgery vs. Radiotherapy Outcome Radical Prostatectomy* Radiation** Survival duration compared to conservative disease

More information

ACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices

ACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices Understanding the performance of active surveillance selection criteria in diverse urology practices Scott R. Hawken BS*,1, Paul R. Womble MD*,1, Lindsey A. Herrel MD 1, Zaojun Ye MS 1, Susan M. Linsell

More information

Important Information for Women with Breast Cancer. what lumpectomy

Important Information for Women with Breast Cancer. what lumpectomy Important Information for Women with Breast Cancer what lumpectomy begins Your most important decisions MammoSite completes Today, more and more women with early-stage breast cancer are able to treat their

More information

PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test

PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication

More information

Questions to ask my doctor: About prostate cancer

Questions to ask my doctor: About prostate cancer Questions to ask my doctor: About prostate cancer Being diagnosed with prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it

More information

Implementation Date: April 2015 Clinical Operations

Implementation Date: April 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:

More information

A guide to prostate cancer clinical trials

A guide to prostate cancer clinical trials 1 A guide to prostate cancer clinical trials In this fact sheet: What is a clinical trial? Why are trials done? What are trials looking into at the moment? How are clinical trials done? Should I take part

More information

DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING

DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING This booklet is what is often called a decision aid. The goals of a decision aid are to help people better understand their medical choices

More information

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj. PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening

More information

PROSTATE CANCER. Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American

PROSTATE CANCER. Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American PROSTATE CANCER 1. Guidelines for Screening Risk Factors Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American High-risk men: Family history of prostate

More information

The PLCO Trial Not a comparison of Screening vs no Screening

The PLCO Trial Not a comparison of Screening vs no Screening PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical

More information

Health Professional and Consumer Views on Involving Breast Cancer Patients in the Multidisciplinary Discussion of Their Disease and Treatment Plan

Health Professional and Consumer Views on Involving Breast Cancer Patients in the Multidisciplinary Discussion of Their Disease and Treatment Plan 1937 Health Professional and Consumer Views on Involving Breast Cancer Patients in the Multidisciplinary Discussion of Their Disease and Treatment Plan Phyllis Butow, MPH, PhD 1,2 James D. Harrison, MPH

More information

A Woman s Guide to Prostate Cancer Treatment

A Woman s Guide to Prostate Cancer Treatment A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate

More information

Questions to Ask My Doctor About Prostate Cancer

Questions to Ask My Doctor About Prostate Cancer Questions to Ask My Doctor Being told you have prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it s treated, and how this

More information

NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER

NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

Recruitment to Cancer Clinical Trials

Recruitment to Cancer Clinical Trials Recruitment to Cancer Clinical Trials Marge Good, RN, BSN, MPH, OCN SWOG CRA Plenary May 1, 2008 Overview Why cancer clinical trials? Why people participate and why they don t? What are the challenges?

More information

Key Messages for Healthcare Providers

Key Messages for Healthcare Providers Cancer Care Ontario: Prostate Cancer Screening with the Prostate- Specific Antigen (PSA) Test Key Messages for Healthcare Providers Considerations for men at average risk Avoid prostate-specific antigen

More information

Disclosure. I have the following relationships with commercial interests:

Disclosure. I have the following relationships with commercial interests: Disclosure Electra Paskett, Ph.D., MPH I have the following relationships with commercial interests: Merck Research grant, in-kind donation Pfizer Stock ownership Meridian Bioscience Stock ownership A

More information

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials

More information

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER 2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of

More information

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy

More information

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative. Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean

More information

Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer Findings by SBU Alert Published Jun 7, 2000 Version 1 Brachytherapy is not widely used in Sweden to treat localized prostate cancer. This treatment method has been available

More information

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate

More information

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Thomas A. Kollmorgen, M.D. Oregon Urology Institute Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men

More information

Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers

Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers James R. Hebert, Sc.D., Cancer Prevention and Control Program, University

More information

Prostate Cancer Treatment Comparison

Prostate Cancer Treatment Comparison Prostate Cancer Treatment Comparison Treatment Comparative Data Outcome Comparison: Surgery vs. Radiotherapy Outcome Radical Prostatectomy* Radiation** Survival duration compared to conservative disease

More information

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers Bard: Prostate Cancer Treatment Bard: Pelvic Organ Prolapse Prostate Cancer An overview of Pelvic Treatment Organ Prolapse Information and Answers A Brief Overview Prostate Anatomy The prostate gland,

More information

The PSA Controversy: Defining It, Discussing It, and Coping With It

The PSA Controversy: Defining It, Discussing It, and Coping With It The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,

More information

Treating Prostate Cancer

Treating Prostate Cancer Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and

More information

Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer

Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer Adam R. Kuykendal, MD; Laura H. Hendrix, MS; Ramzi G. Salloum, PhD; Paul A. Godley, MD, PhD; Ronald C. Chen, MD, MPH No conflicts

More information

Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide

Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide A diagnosis of breast cancer is never easy, but today there are more treatment options than ever before. A breast

More information

PRACTICE FRAMEWORK AND COMPETENCY STANDARDS FOR THE PROSTATE CANCER SPECIALIST NURSE

PRACTICE FRAMEWORK AND COMPETENCY STANDARDS FOR THE PROSTATE CANCER SPECIALIST NURSE PRACTICE FRAMEWORK AND COMPETENCY STANDARDS FOR THE PROSTATE CANCER SPECIALIST NURSE MARCH 2013 MONOGRAPHS IN PROSTATE CANCER OUR VISION, MISSION AND VALUES Prostate Cancer Foundation of Australia (PCFA)

More information

Nancy Schoenborn, MD Sei Lee MD, MAS Craig Pollack MD, MHS Alexander Smith, MD, MS, MPH Mara Schonberg, MD, MPH

Nancy Schoenborn, MD Sei Lee MD, MAS Craig Pollack MD, MHS Alexander Smith, MD, MS, MPH Mara Schonberg, MD, MPH Nancy Schoenborn, MD Sei Lee MD, MAS Craig Pollack MD, MHS Alexander Smith, MD, MS, MPH Mara Schonberg, MD, MPH None Describe the importance of incorporating prognosis in care decisions of older adults

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

Prostate cancer is the second most

Prostate cancer is the second most Treatment Options for Localized Prostate Cancer RAVINDER MOHAN, MD, PhD, and PAUL F. SCHELLHAMMER, MD Eastern Virginia Medical School, Norfolk, Virginia In the United States, more than 90 percent of prostate

More information

A Guide to Clinical Trials

A Guide to Clinical Trials A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Clinical trial enrollment among older cancer patients

Clinical trial enrollment among older cancer patients Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department

More information

Prostate Cancer Screening

Prostate Cancer Screening Prostate Cancer Screening The American Cancer Society and Congregational Health Ministry Team June Module To access this module via the Web, visit www.cancer.org and type in congregational health ministry

More information

TITLE: The Impact Of Prostate Cancer Treatment-Related Symptoms On Low-Income Latino Couples

TITLE: The Impact Of Prostate Cancer Treatment-Related Symptoms On Low-Income Latino Couples AD Award Number: W81WH-07-1-0069 TITLE: The Impact Of Prostate Cancer Treatment-Related Symptoms On Low-Income Latino Couples PRINCIPAL INVESTIGATOR: Sally L. Maliski, Ph.D., R.N. CONTRACTING ORGANIZATION:

More information

The Center for Cancer Care. Comprehensive and compassionate care

The Center for Cancer Care. Comprehensive and compassionate care The Center for Cancer Care Comprehensive and compassionate care Welcome to the Center for Cancer Care The Center for Cancer Care at Exeter Hospital provides comprehensive, compassionate care for a wide

More information

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate

More information

Advice to patients about the PSA (prostate-specific antigen) blood test: frequently-asked questions

Advice to patients about the PSA (prostate-specific antigen) blood test: frequently-asked questions Advice to patients about the PSA (prostate-specific antigen) blood test: frequently-asked questions What is the PSA blood test? If you want more information before deciding to have this test, it is important

More information

The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development:

The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development: The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development: Title: Non-Recommended PSA-Based Screening Description: The percentage

More information

HEALTH SYSTEM PERFORMANCE INTERACTIVE INDICATORS WEBSITE PUBLIC ENGAGEMENT SUMMARY REPORT

HEALTH SYSTEM PERFORMANCE INTERACTIVE INDICATORS WEBSITE PUBLIC ENGAGEMENT SUMMARY REPORT HEALTH SYSTEM PERFORMANCE INTERACTIVE INDICATORS WEBSITE PUBLIC ENGAGEMENT SUMMARY REPORT PAGES TABLE OF CONTENTS INTRODUCTION 1 KEY FINDINGS: ONLINE AND IN-PERSON ENGAGEMENT 2 FINDINGS: ONLINE ENGAGEMENT

More information

How To Teach Health Care Policy To Radiation Oncology

How To Teach Health Care Policy To Radiation Oncology Teaching and Assessing Systems-Based Practice: A Pilot Course in Health Care Policy, Finance, and Law for Radiation Oncology Residents James D. Mitchell, MD Preeti Parhar, MD Ashwatha Narayana, MD Abstract

More information

Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma

Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma 1773 Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma Leslie R. Schover, Ph.D. 1 Rachel T. Fouladi, Ph.D. 1 Carla L. Warneke, M.S. 1 Leah Neese, M.A. 1 Eric A. Klein, M.D. 2 Craig

More information

PSA After Radiation for Prostate Cancer

PSA After Radiation for Prostate Cancer Review Article [1] May 01, 2004 By Deborah A. Kuban, MD [2], Howard D. Thames, PhD [3], and Larry B. Levy, MS [4] The introduction of prostate-specific antigen (PSA) as a reliable tumor marker for prostate

More information

Factors Affecting Patient Recruitment in an Acute Rehabilitation Randomized Controlled Trial

Factors Affecting Patient Recruitment in an Acute Rehabilitation Randomized Controlled Trial Factors Affecting Patient Recruitment in an Acute Rehabilitation Randomized Controlled Trial Natasha Lannin, Anne Cusick OBJECTIVE. To evaluate factors associated with randomized controlled trial patient

More information

Correlates of Referral Practices of General Surgeons to Plastic Surgeons for Mastectomy Reconstruction

Correlates of Referral Practices of General Surgeons to Plastic Surgeons for Mastectomy Reconstruction 1715 Correlates of Referral Practices of General Surgeons to Plastic Surgeons for Mastectomy Reconstruction Amy K. Alderman, MD, MPH 1,2 Sarah T. Hawley, PhD 2,3 Jennifer Waljee, MD 4 Monica Morrow, MD

More information

855-DRSAMADI or 212-241-8779

855-DRSAMADI or 212-241-8779 SMART SURGERY NEWS MARCH 2013 Dr. David Samadi 855-DRSAMADI or 212-241-8779 YOUR PROSTATE CANCER NEWS PREVENTION DIAGNOSIS TREATMENT LIFE AFTER PROSTATE CANCER PREVENTION Prostate Cancer Need-to-Knows

More information

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Prostate Cancer Epidemiology: 2009 Estimated new cases: 230,000 Estimated deaths:

More information

SRO Tutorial: Prostate Cancer Treatment Options

SRO Tutorial: Prostate Cancer Treatment Options SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,

More information

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH). Prostate Cancer Definition Prostate cancer is cancer that starts in the prostate gland. The prostate is a small, walnut-sized structure that makes up part of a man's reproductive system. It wraps around

More information

Guide to Best Practices in a Comprehensive Prostate Cancer Program

Guide to Best Practices in a Comprehensive Prostate Cancer Program Guide to Best Practices in a Comprehensive Prostate Cancer Program This Guide to Best Practices in a Comprehensive Prostate Cancer Program is designed to assist community centers by outlining the process

More information

The human sexuality education of physicians in North American medical schools

The human sexuality education of physicians in North American medical schools (2003) 15, Suppl 5, S41 S45 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir The human sexuality education of physicians in North American medical schools DS Solursh

More information

1. What is the prostate-specific antigen (PSA) test?

1. What is the prostate-specific antigen (PSA) test? 1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor

More information

A Prostate and Genitourinary Multidisciplinary Oncology Clinic in a Multi-Hospital System by Richard B. Reiling, MD, FACS

A Prostate and Genitourinary Multidisciplinary Oncology Clinic in a Multi-Hospital System by Richard B. Reiling, MD, FACS A Prostate and Genitourinary Multidisciplinary Oncology Clinic in a Multi-Hospital System by Richard B. Reiling, MD, FACS In Brief At Presbyterian Cancer Center in Charlotte, N.C., we are seeing a higher

More information

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of

More information

Guidelines for Management of Renal Cancer

Guidelines for Management of Renal Cancer Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated

More information

Training Requirements for the Specialty of Radiation Oncology

Training Requirements for the Specialty of Radiation Oncology Association internationale sans but lucratif AVENUE DE LA COURONNE, 20 BE- 1050 BRUSSELS www.uems.net International non-profit organisation T +32 2 649 51 64 F +32 2 640 37 30 info@uems.net Training Requirements

More information

Participating in Alzheimer s Disease Clinical Trials and Studies

Participating in Alzheimer s Disease Clinical Trials and Studies Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the

More information

Treating Localized Prostate Cancer A Review of the Research for Adults

Treating Localized Prostate Cancer A Review of the Research for Adults Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized

More information

The Patient Journey in High Resolution

The Patient Journey in High Resolution The Patient Journey in High Resolution Innovating for a richer understanding of the patient journey By Jackie Ilacqua Tel +1 201-574-8079 Email jackie.ilacqua@ipsos.com 1 xx-xx-xx Achieving a rich, yet

More information

HEALTH NEWS PROSTATE CANCER THE PROSTATE

HEALTH NEWS PROSTATE CANCER THE PROSTATE HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized

More information